Question · Q1 2022
Nathan Weinstein of Aegis Capital asked about the strategic importance of developing a subcutaneous formulation for CM-101 in PSC and SSc, and inquired about the expected trend for operating expenses for the remainder of the year.
Answer
Interim CMO Dr. David Weiner explained that while an IV route is acceptable for these high-unmet-need diseases, a subcutaneous formulation adds significant patient convenience and is critical for potential expansion into other indications. CFO, COO & EVP Don Marvin stated that operating expenses are expected to trend upwards through the rest of the year as the PSC trial expands and the SSc trial is initiated in Q4.